FDA And CMS Parallel Reviews Will Begin With Device Pilot Program
This article was originally published in The Gray Sheet
Executive Summary
FDA and CMS' consideration of parallel medical product reviews will begin in earnest with a planned pilot program for devices, the agencies say
You may also be interested in...
IPAB Raised At Debate; Romney Advisor Skeptical Board Will Ever Meet, Even If Obama Wins
Strict conflict-of-interest restrictions will make it very challenging to get people confirmed to serve on the Independent Payment Advisory Board, established under health reform, according to a top advisor to Mitt Romney. IPAB was a contentious issue in last week’s presidential debate.
Cypher’s Impact On Regulatory, Reimbursement Landscape
During its rise and fall as the first device on the “blockbuster” drug-eluting stent market, Cordis' Cypher sirolimus-eluting coronary stent helped break new ground on both regulatory and reimbursement fronts.
Cypher’s Impact On Regulatory, Reimbursement Landscape
During its rise and fall as the first device on the “blockbuster” drug-eluting stent market, Cordis' Cypher sirolimus-eluting coronary stent helped break new ground on both regulatory and reimbursement fronts.